KLRA (Kailera Therapeutics) Other Operating Expense: $ Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KLRA Kailera Therapeutics Inc KLRA
11 GF Score
Price $17.32
! 1 Warning Sign
View Full Analysis

What is Kailera Therapeutics Other Operating Expense?

Kailera Therapeutics KLRA +2.24% 11 Other Operating Expense is $ Mil as of Dec. 2025. GuruFocus rates KLRA with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Kailera Therapeutics's Other Operating Expense for the six months ended in Dec. 2025 was $0.00 Mil. Kailera Therapeutics does not have enough years/quarters to calculate its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025.

Kailera Therapeutics's quarterly Other Operating Expense stayed the same from . 20 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.00 Mil).

Kailera Therapeutics's annual Other Operating Expense stayed the same from . 20 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.00 Mil).

Kailera Therapeutics Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Kailera Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kailera Therapeutics Other Operating Expense Chart

Kailera Therapeutics Annual Data
Trend Dec24 Dec25
Other Operating Expense
0.00 0.00

Kailera Therapeutics Semi-Annual Data
Dec24 Dec25
Other Operating Expense 0.00 0.00
KLRA
11GF Score
Kailera Therapeutics Inc KLRA
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kailera Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $ Mil mean?
Kailera Therapeutics (KLRA) has a Other Operating Expense of $ Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Kailera Therapeutics and its competitors.
Is Kailera Therapeutics' Other Operating Expense too high?
Kailera Therapeutics' current Other Operating Expense is $ Mil. Overall, Kailera Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Kailera Therapeutics' Other Operating Expense compare to VCEL and NUVB?
Kailera Therapeutics' Other Operating Expense of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Kailera Therapeutics and its competitors. Kailera Therapeutics's current Other Operating Expense is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kailera Therapeutics stock overvalued right now?
Kailera Therapeutics (KLRA) has a current Other Operating Expense of $ Mil. The current Other Operating Expense is $ Mil. Kailera Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Kailera Therapeutics (KLRA), the current Other Operating Expense is $ Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kailera Therapeutics Business Description

Address 180 Third Avenue, 4th Floor, Waltham, MA, USA, 02451
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
11GF Score

Get the complete analysis for KLRA

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.32
Price